Accelerated approvals for cancer drugs is a good idea in theory. This US Food and Drug Administration (FDA) pathway allows promising new cancer agents to reach the market, and patients, sooner. But ...
SAN DIEGO, June 9, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...
The HHS Office of Inspector General report emphasizes the need for better documentation and oversight in the FDA's accelerated approval pathway. The accelerated approval pathway is crucial for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results